- Home
- MDAI vs APLT Comparison
MDAI vs APLT Comparison
Compare MDAI & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDAI
- APLT
- Stock Information
- Founded
- MDAI 2013
- APLT 2016
- Country
- MDAI United States
- APLT United States
- Employees
- MDAI N/A
- APLT N/A
- Industry
- MDAI Medical/Dental Instruments
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- MDAI Health Care
- APLT Health Care
- Exchange
- MDAI Nasdaq
- APLT Nasdaq
- Market Cap
- MDAI 51.5M
- APLT 44.0M
- IPO Year
- MDAI N/A
- APLT 2019
- Fundamental
- Price
- MDAI $2.68
- APLT $0.42
- Analyst Decision
- MDAI Strong Buy
- APLT Buy
- Analyst Count
- MDAI 2
- APLT 7
- Target Price
- MDAI $4.75
- APLT $6.10
- AVG Volume (30 Days)
- MDAI 712.3K
- APLT 2.6M
- Earning Date
- MDAI 08-11-2025
- APLT 08-06-2025
- Dividend Yield
- MDAI N/A
- APLT N/A
- EPS Growth
- MDAI N/A
- APLT N/A
- EPS
- MDAI N/A
- APLT N/A
- Revenue
- MDAI $29,962,000.00
- APLT $265,000.00
- Revenue This Year
- MDAI N/A
- APLT $1,768.13
- Revenue Next Year
- MDAI $15.14
- APLT $292.85
- P/E Ratio
- MDAI N/A
- APLT N/A
- Revenue Growth
- MDAI 55.21
- APLT N/A
- 52 Week Low
- MDAI $0.82
- APLT $0.30
- 52 Week High
- MDAI $3.25
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- MDAI 59.26
- APLT 59.95
- Support Level
- MDAI $2.56
- APLT $0.32
- Resistance Level
- MDAI $3.21
- APLT $0.36
- Average True Range (ATR)
- MDAI 0.21
- APLT 0.04
- MACD
- MDAI 0.02
- APLT 0.01
- Stochastic Oscillator
- MDAI 53.47
- APLT 92.91
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.